Back to search

Peptide record

TPDB05490

Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity standard
14 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05490
Antibacterial Anticancer Antifungal Antiparasitic Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 DRAMP Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb APD_complete APD_hemolytic Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 14-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, DRAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
LNLKALLAVAKKIL
Physicochemical Analysis
C72H134N18O16
RDCEQGHMFPSTWY
L
1507.97
10.84
3
0
10
+3
-0.16
1.279
209.29
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
3
A
0
R
1
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
5
L
3
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 5 K: 3 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
14
C72H134N18O16
1507.97
10.84
+3
-0.16
1.279
Evidence Records 36 records
Evidence 1 Activity

Activity

MIC
Antibacterial
4-8 µM

Target

Enterococcus faecalis

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antibacterial
DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and
Evidence 2 Activity

Activity

MIC
Antibacterial
2-32 µM

Target

Staphylococcus aureus or MRSA

Source & Reference

DRAMP

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, a
Evidence 3 Activity

Activity

MIC
Antibacterial
4-8 µM

Target

Escherichia coli

Source & Reference

DRAMP

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B.
Evidence 4 Activity

Activity

MIC
Antibacterial
8-64 µM

Target

Pseudomonas aeruginosa

Source & Reference

DRAMP

Other

against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM)
Evidence 5 Activity

Activity

MIC
Antibacterial
4-8 µM

Target

Candida albicans

Source & Reference

DRAMP

Other

, S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313
Evidence 6 Activity

Activity

MIC
Antibacterial
4 µM

Target

B. cereus ATCC 11778

Source & Reference

DRAMP

Other

M), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combin
Evidence 7 Activity

Activity

MIC
Antibacterial
8 µM

Target

L. monocytogenes ATCC 15313

Source & Reference

DRAMP

Other

and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 8 Activity

Activity

MIC
Antibacterial
32 µM

Target

S. enterica ATCC 13076

Source & Reference

DRAMP

Other

inst Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 9 Activity

Activity

MIC
Antifungal
4-8 µM

Target

Enterococcus faecalis

Source & Reference

DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and
Evidence 10 Activity

Activity

MIC
Antifungal
2-32 µM

Target

Staphylococcus aureus or MRSA

Source & Reference

DRAMP CAFPdb Antifungipept

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, a
Evidence 11 Activity

Activity

MIC
Antifungal
4-8 µM

Target

Escherichia coli

Source & Reference

DRAMP CAFPdb Antifungipept

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B.
Evidence 12 Activity

Activity

MIC
Antifungal
8-64 µM

Target

Pseudomonas aeruginosa

Source & Reference

DRAMP CAFPdb Antifungipept

Other

against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM)
Evidence 13 Activity

Activity

MIC
Antifungal
4-8 µM

Target

Candida albicans

Source & Reference

DRAMP CAFPdb Antifungipept

Other

, S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313
Evidence 14 Activity

Activity

MIC
Antifungal
4 µM

Target

B. cereus ATCC 11778

Source & Reference

DRAMP CAFPdb Antifungipept

Other

M), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combin
Evidence 15 Activity

Activity

MIC
Antifungal
8 µM

Target

L. monocytogenes ATCC 15313

Source & Reference

DRAMP CAFPdb Antifungipept

Other

and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 16 Activity

Activity

MIC
Antifungal
32 µM

Target

S. enterica ATCC 13076

Source & Reference

DRAMP CAFPdb Antifungipept

Other

inst Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 17 Activity

Activity

MIC
Antiparasitic
4-8 µM

Target

Enterococcus faecalis

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and
Evidence 18 Activity

Activity

MIC
Antiparasitic
2-32 µM

Target

Staphylococcus aureus or MRSA

Source & Reference

DRAMP

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, a
Evidence 19 Activity

Activity

MIC
Antiparasitic
4-8 µM

Target

Escherichia coli

Source & Reference

DRAMP

Other

Active against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B.
Evidence 20 Activity

Activity

MIC
Antiparasitic
8-64 µM

Target

Pseudomonas aeruginosa

Source & Reference

DRAMP

Other

against E. faecalis (MIC 4-8 uM), S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM)
Evidence 21 Activity

Activity

MIC
Antiparasitic
4-8 µM

Target

Candida albicans

Source & Reference

DRAMP

Other

, S. aureus or MRSA (MIC 2-32 uM), E. coli (MIC 4-8 uM), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313
Evidence 22 Activity

Activity

MIC
Antiparasitic
4 µM

Target

B. cereus ATCC 11778

Source & Reference

DRAMP

Other

M), P. aeruginosa (MIC 8-64 uM), and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combin
Evidence 23 Activity

Activity

MIC
Antiparasitic
8 µM

Target

L. monocytogenes ATCC 15313

Source & Reference

DRAMP

Other

and C. albicans (MIC 4-8 uM). Also, active against Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 24 Activity

Activity

MIC
Antiparasitic
32 µM

Target

S. enterica ATCC 13076

Source & Reference

DRAMP

Other

inst Gram+ B. cereus ATCC 11778 (MIC 4 uM), L. monocytogenes ATCC 15313 (MIC 8 uM), Gram- S. enterica ATCC 13076 (MIC 32 uM) (combined with new data from ref for AP4034).
Evidence 25 Activity

Activity

IC50
Toxicity
57.15 µM
Cytotoxic
IC50 | 57.15 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
Evaluation of the bioactivity of a mastoparan peptide from wasp venom and of its analogues designed through targeted engineering. | Int J Biol Sci | 2018
Evidence 26 Activity

Activity

50% Hemolysis
Toxicity
40.11 µM
Hemolytic Cytotoxic
50% Hemolysis | 40.11 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
Evaluation of the bioactivity of a mastoparan peptide from wasp venom and of its analogues designed through targeted engineering. | Int J Biol Sci | 2018
Evidence 27 Activity

Activity

10% Hemolysis
Toxicity
64 µM
Hemolytic Cytotoxic
10% Hemolysis | 64 | µM | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria. | Eur J Pharm Sci | 2020
Evidence 28 Activity

Activity

60% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
60% Hemolysis | 256 | µM | target cell: Mouse erythrocytes

Target

Mouse erythrocytes

Source & Reference

NA
DBAASP
Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria. | Eur J Pharm Sci | 2020
Evidence 29 Activity

Activity

90% Killing
Toxicity
128 µM
Cytotoxic
90% Killing | 128 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria. | Eur J Pharm Sci | 2020
Evidence 30 Activity

Activity

IC50
Toxicity
16 µM
Cytotoxic
IC50 | 16 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Newly designed antimicrobial peptides with potent bioactivity and enhanced cell selectivity prevent and reverse rifampin resistance in Gram-negative bacteria. | Eur J Pharm Sci | 2020
Evidence 31 Activity

Activity

<5% Hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
<5% Hemolysis | 8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Naturally occurring and artificially designed antimicrobial peptides: a comparative study of Mastoparan C and BP52 | Med Chem Res | 2024
Evidence 32 Activity

Activity

77.1% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
77.1% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Naturally occurring and artificially designed antimicrobial peptides: a comparative study of Mastoparan C and BP52 | Med Chem Res | 2024
Evidence 33 Activity

Activity

<5% Hemolysis
Toxicity
8 µM
Hemolytic Cytotoxic
<5% Hemolysis | 8 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of hydrophobicity on the antimicrobial activity of helical antimicrobial peptides: a study focusing on three mastoparans. | Mol Divers | 2024
Evidence 34 Activity

Activity

62% Hemolysis
Toxicity
128 µM
Hemolytic Cytotoxic
62% Hemolysis | 128 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Influence of hydrophobicity on the antimicrobial activity of helical antimicrobial peptides: a study focusing on three mastoparans. | Mol Divers | 2024
Evidence 35 Activity

Activity

IC50
Toxicity
57.15 µM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.29904274]50% hemolysis against horse erythrocytes at 40.11 µM.##[Ref.33285267]10% hemolysis against mouse erythrocytes at 64 µM 60% hemolysis against mouse erythrocytes at 256 µM. | Cytotoxicity: [Ref.29904274]Cytotoxicity:Human microvascular endothelial cells HMEC-1(IC50=57.15 µM).##[Ref.33285267]90% Killing against Human embryonic kidney HEK293T cells at 128 µM Human embryonic kidney HEK293T cells(IC50=16 µM).

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Pharm Sci. 2021 Mar 1 158:105665.##Int J Biol Sci. 2018 Apr 25 14(6):599-607.
Evidence 36 Hemolysis

Source & Reference

APD_complete APD_hemolytic PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.